Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $1,442,150.92 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 40,831 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $35.32, for a total value of $1,442,150.92. Following the transaction, the director now owns 193,296 shares in the company, valued at approximately $6,827,214.72. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Dirk Kersten also recently made the following trade(s):

• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total transaction of $2,894,530.95.

Dyne Therapeutics Stock Down 0.7 %

Shares of DYN stock opened at $34.62 on Friday. Dyne Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.45. The business has a fifty day simple moving average of $40.41 and a 200 day simple moving average of $33.78. The company has a market cap of $3.03 billion, a P/E ratio of -8.72 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.02. As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Oppenheimer reissued an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. JPMorgan Chase & Co. boosted their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th. Piper Sandler restated an “overweight” rating and set a $53.00 price objective on shares of Dyne Therapeutics in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, September 4th. Finally, Stifel Nicolaus raised their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its holdings in shares of Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after purchasing an additional 669 shares during the last quarter. Amalgamated Bank boosted its position in Dyne Therapeutics by 39.9% during the 2nd quarter. Amalgamated Bank now owns 2,792 shares of the company’s stock worth $99,000 after buying an additional 796 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Dyne Therapeutics by 28.0% during the 1st quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock worth $167,000 after acquiring an additional 1,291 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Dyne Therapeutics during the 2nd quarter worth approximately $203,000. Finally, Farallon Capital Management LLC acquired a new position in Dyne Therapeutics in the 2nd quarter valued at approximately $212,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.